Arbeitsgemeinschaft Gynäkologische Onkologie e.V. (AGO)

Research facility


Location: Taufkirchen, Germany (DE) DE

ISNI: -

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Clinical and Molecular Evaluation of HER2-Low and HER2-Ultralow Breast Cancer in the Penelope-B Clinical Trial Cohort (2026) Denkert C, Rachakonda S, Pehl A, Marmé F, Martin M, Karn T, Untch M, et al. Journal article Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials (2025) Conforti F, Holtschmidt J, Nekljudova V, Sala I, Pagan E, Solbach C, Untch M, et al. Journal article Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial (2025) Harter P, Marth C, Mouret-Reynier MA, Cropet C, Lorusso D, Guerra-Alía EM, Matsumoto T, et al. Journal article Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial (2023) Lorusso D, Mouret-Reynier MA, Harter P, Cropet C, Caballero C, Wolfrum-Ristau P, Satoh T, et al. Journal article Carboplatin/pegylated liposomal doxorubicin/bevacizumab (CD-BEV) vs. carboplatin/gemcitabine/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer: A prospective randomized phase III ENGOT/GCIG-Intergroup study (AGO study group, AGO-Austria, ANZGOG, GINECO, SGCTG) (2018) Pfisterer J, Dean AP, Baumann K, Rau J, Harter P, Joly F, Sehouli J, et al. Conference contribution